Jenna Philpott is a trainee healthcare and pharmaceutical reporter. Coming from a scientific background, Jenna has expertise in biochemistry, genetics and cancer science. Jenna previously wrote freelance articles focused on oncology and healthcare.
EVŌQ Nano will target the catheter market with EVQ-218 nanoparticle, where healthcare-associated infections often manifest.
In the study investigating Pelvital’s Flyte device, 71% of participants achieved continence in two to 12 weeks.
PrimeC demonstrated a statistically significant slowing of disease progression compared to the placebo.
Tharimmune is planning to advance TH104 into a Phase II clinical trial later this year, funded by an $11m public offering from 2023.
Applied plans to submit a new drug application following the announcement of positive interim data from its Phase III trial.
Give your business an edge with our leading industry insights.
Exparel gained approval from the US Food and Drug Administration (FDA) for the expanded label to include sciatic nerve block in the popliteal fossa following these positive results.
Osivax has vaccinated the first participant with the investigational sarbecovirus vaccine OVX033 in Paris, commencing the start of the 48-participant trial.
RBI-4000 induced neutralising antibody titres at levels that exceeded the WHO’s defined surrogate level of protection for rabies virus.
Sana selected Curavit as its VCRO for the decentralised clinical trial of its Sana virtual-reality device to treat symptoms of PTSD.
The results, presented at the 2024 annual meeting of the American Academy of Orthopaedic Surgeons (AAOS), showed comparable revision rates.